Physician profile
Joyce Kong
NPI 1740819879
$3,118.50
in general payments reported to CMS, 2019-2025
17 companies · $2,351 in 2025
The $2,351 reported for 2025 was more than what 95% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $16.87 · 2024: $751 · 2025: $2,351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,101.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.92 | 2024-2025 | |
| Pfizer INC. | $342.21 | 2024-2025 | |
| Janssen Biotech, INC. | $330.30 | 2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $306.49 | 2024-2025 | Zoryve |
| Ucb, INC. | $180.22 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $178.62 | 2024-2025 | Ebglyss, Olumiant, Taltz |
| Regeneron Healthcare Solutions, INC. | $173.66 | 2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $173.61 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.32 | 2022-2024 | Spevigo |
| Incyte Corporation | $144.39 | 2024-2025 | Opzelura |
| Genzyme Corporation | $141.39 | 2024 | |
| Amgen INC. | $110.09 | 2025 | Otezla |
| Leo Pharma INC. | $102.98 | 2025 | Anzupgo |
| Mayne Pharma Commercial LLC | $44.75 | 2025 | |
| Dermavant Sciences, INC. | $36.36 | 2024 | Vtama |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $35.10 | 2024 | Sotyktu |
| Organon LLC | $27.09 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joyce Kong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.